Pharmacogenetics of gemtuzumab-associated hepatic sinusoidal occlusion syndrome after hematopoietic stem cell transplant.
Aplenc
Richard
R
Pediatric Oncology, Children's Hospital of Philadelphia, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA. raplenc@cceb.med.upenn.edu
Vachani
Anil
A
Han
Peggy
P
Glatfelter
Wendy
W
Sievers
Eric L
EL
D000617:Aminoglycosides / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced*; D006801:Humans; D010597:Pharmacogenetics
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab